Marshall Wace’s Petros Pharmaceuticals PTPI Stock Holding History

Marshall Wace’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-525	Closed	-$205K	–	3761
2022 Q1	$205K	Sell	525 -451	-46%	-$190K	﹤0.01%	3095
2021 Q4	$813K	Buy	+976	New	+$572K	﹤0.01%	2567

Other funds holding PTPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Marshall Wace's PTPI Position: Q2 2022 in Review

Marshall Wace sold out of Petros Pharmaceuticals (PTPI) in Q2 2022, closing a stake of 525 shares — an estimated $205K sold.

Marshall Wace first reported a position in PTPI in Q4 2021 and held it in 2 quarters. The position peaked at $813K in Q4 2021. 13 funds tracked by Wall St. Rank hold PTPI as of Q2 2022.

Marshall Wace reported no remaining Petros Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Marshall Wace sold 525 Petros Pharmaceuticals shares in Q2 2022, an estimated $205K.
Marshall Wace first reported a position in Petros Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Marshall Wace's Petros Pharmaceuticals position peaked at $813K in Q4 2021.
13 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.